Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

NCT06868836
recruitingphase_2

JS212 Combination Therapies in Metastatic Colorectal Cancer

NCT07503756
recruitingphase_2

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT07484724

Clinical Trials (3)

Showing 3 of 3 trials
NCT06868836Phase 2

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Recruiting
NCT07503756Phase 2

JS212 Combination Therapies in Metastatic Colorectal Cancer

Recruiting
NCT07484724Phase 2

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3